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A pilot ﬁeld trial of the TSOL18 vaccine was undertaken in Cameroon. Two hundred and forty, 2–3 month-
old piglets were distributed to 114 individual households in pairs. Vaccinated animals received three
immunisations with 200 lg TSOL18 plus 5 mg Quil A and 30 mg/kg oxfendazole at the time of the second
immunisation. Necropsies were undertaken when the pigs were approximately 12 months of age. Viable
Taenia solium cysticerci were identiﬁed in 20 control pigs (prevalence 19.6%); no cysticerci were found in
any of the vaccinated animals (P < 0.0001). Combined application of TSOL18 vaccination and a single
oxfendazole treatment in pigs may be a relatively simple and sustainable procedure that has the potential
to control T. solium transmission in endemic areas and, indirectly, reduce the number of new cases of
neurocysticercosis in humans.
 2010 Australian Society for Parasitology Inc. Published by Elsevier Ltd.Taenia solium is a taeniid cestode parasite which is transmitted
between humans and pigs, with pigs acting as the intermediate
host. While humans are the obligatory deﬁnitive host for the par-
asite, they can also become infected with the metacestode life
cycle stage and in such cases the parasite has a propensity to infect
the brain, causing the disease neurocysticercosis. Neurocysticerco-
sis is a debilitating disease prevalent in many parts of the develop-
ing world where pigs are allowed to roam free and where latrines
are not available or not used (Garcia et al., 2003; Garcia and Del
Brutto, 2005). The disease is also a burden in developed countries
where immigrants infected with the adult worm can infect other
citizens or arrive already suffering neurocysticercosis (Schantz
et al., 1992).
Neurocysticercosis is a disease associated with poverty.
Improvements in public sanitation in developed countries have
led to the disappearance of T. solium transmission in many devel-
oped countries. Although the disease has been identiﬁed as having
the potential to be eradicated on a global scale (Schantz et al.,
1993), limitations in the usefulness of available tools have inhib-
ited the initiation of widespread T. solium control programs and
those that have been undertaken to date have achieved only a tem-
poral decrease in disease transmission (Garcia and Del Brutto,Inc. Published by Elsevier Ltd.
fax: +61 (0) 3 9741 5461.
ightowlers).
Op2005). A problem for T. solium control is that, although the adult
tapeworm in humans is readily killed by treatment of infected per-
sons with anthelmintics, in an environment where there are many
pigs infected with the parasite new human tapeworm infections
can be established and transmission of the disease can continue.
Another potential control measure for T. solium is the treatment
of infected pigs with anthelmintics to kill the muscle cysts. Taenia
solium cysticerci in the muscles of pigs are killed following a single
oral treatment with 30 mg/kg of the benzimidazole drug oxfendaz-
ole (Gonzales et al., 1996; Gonzalez et al., 1997; Sikasunge et al.,
2008). However, there are two limitations to utilisation of this as
an effective T. solium control measure. Following anthelmintic
treatment, pigs that were not previously infected with T. solium re-
main susceptible to infection. Any infections acquired after anthel-
mintic treatment would be mature and capable of transmitting the
disease following a period of approximately 6 weeks after the
infection occurred. Unless the animals were slaughtered within
this time window, anthelmintic treatment of pigs could not be re-
lied upon to eliminate the potential for treated animals to transmit
the disease. Coordinating anthelmintic treatment of pigs with their
sale and slaughter, taking into consideration a withholding period
for the animals after application of the chemical and the nature of
most environments in which T. solium occurs, could be problem-
atic. The second limitation to the use of anthelmintic treatment
of pigs as a control measure for T. solium relates to the occurrenceen access under CC BY license.  
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the inﬂammatory reactions that occur in response to the anthel-
mintic-mediated death of cysticerci in the muscles. These lesions
are not of concern for transmission of T. solium because the parasite
is dead; however, they are unsightly and if present in signiﬁcant
numbers, make the meat unsuitable for sale. The lesions persist
for as long as 6 months after pig treatment (Sikasunge et al., 2008).
Vaccination has been identiﬁed as a potentially valuable new
tool for prevention of T. solium transmission (Lightowlers, 1999).
While it may be potentially possible to vaccinate the human pop-
ulation against T. solium, a less expensive option is the vaccination
of pigs to prevent the disease transmission thereby indirectly
reducing the number of new human cases of neurocysticercosis.
Several candidate vaccines have been developed and one has
shown some promise in ﬁeld trials (Huerta et al., 2001; Sciutto
et al., 2007; Morales et al., 2008). The TSOL18 vaccine has proven
to be the most effective vaccine against T. solium, with independent
experimental vaccine trials carried out in Mexico, Peru, Cameroon
and Honduras inducing 99.3–100% protection against an experi-
mental challenge infection with T. solium eggs in pigs (Flisser
et al., 2004; Gonzalez et al., 2005; Lightowlers, 2006).
The far-Northern region of Cameroon is highly endemic for T.
solium (Assana et al., 2001, 2010; Zoli et al., 2003). In this region
we undertook the ﬁrst ﬁeld evaluation of the TSOL18 vaccine in
pigs against a natural exposure to the parasite acquired through
the consumption of the faeces of humans infected with T. solium
taeniasis.
The vaccine ﬁeld trial was conducted from October 2008 to July
2009 in the Mayo-Danay administrative department of the Far
North region of Cameroon. This region is characterised by having
Sahelian-Sudanese climate (M’Biandoun et al., 2003) with a short
rainy season (June–September) and a long dry season (October–
May). The total human population is about 600,000 inhabitants.
Predominant ethnic groups in the rural areas are animistic or
Christian. Forty-one villages (Fig. 1) and 114 pig farms were se-
lected on the basis of epidemiological information collected from
a survey of the population and serological results on pigs (Assana
et al., 2010). Coordinates of each pig farm were obtained by means
of the Global Positioning Systems (GPS) using a handheld Garmin
eMap device (Garmin, Olathe, USA). The region and village loca-
tions are depicted in Fig. 1 (Arcview GIS 3.2 (Environmental System
Research Institute, Redlands, USA)).Fig. 1. Location of the villages in the Mayo-Danay district of far north Cameroon in whi
vaccine against Taenia solium infection.The general strategy adopted for the trial was to vaccinate pig-
lets at 2–3 months of age and give a booster immunisation 4 weeks
later. At the time of the second immunisation, the pigs were given
oxfendazole to kill any parasites that may already have established
in the animals prior to vaccination. Controls were similarly treated
with anthelmintic so that any effects of the procedure could be
associated with vaccination per se. Controls were not vaccinated
because multiple, independent previous experiments had indi-
cated that vaccination of pigs with all components of the vaccine,
other than the TSOL18 protein itself, did not prevent T. solium
infection in pigs while the majority of pigs vaccinated with TSOL18
have no parasites following an experimental challenge infection
(Flisser et al., 2004; Gonzalez et al., 2005). Vaccinated pigs were gi-
ven an additional booster immunisation because at the time the
trial was initiated there was insufﬁcient information available to
predict whether two immunisations would have been sufﬁcient
to protect the pigs for the duration of the trial.
Vaccinations started at the end of the rainy season after which
pigs were allowed to roam free during the dry season. Typical farm
practice was for the pigs to roam free around the village all day, re-
turn to their owners for feeding in the evening and be penned over-
night. Two hundred and eighty, three month-old piglets which
appeared to be without T. solium infection (determined using ton-
gue examination) were purchased from amongst the village farms
and the animals were distributed in matched pairs (one vaccinated,
one control) in 114 selected pig farms. Piglets were doubly labelled
using both a numbered earring and a microchip.
Sample sizes were calculated using Fisher’s exact test such that
differences between control and vaccinated groups would be iden-
tiﬁed with 80% power where the vaccine showed 90% efﬁcacy, the
prevalence of cysticercosis in control animals was 10% and differ-
ences between the groups were detected at the P < 0.05 level.
One hundred and six pairs were required, however, after allowing
for possible losses a total of 240 pigs (120 pairs) were placed in the
114 selected farms, some of which were allocated two or three
pairs of animals.
TSOL18 was expressed in Escherichia coli, puriﬁed and lyophi-
lised prior to transport to Cameroon as described by Flisser et al.
(2004) and Gonzalez et al. (2005) except that each dose of vaccine
contained 200 lg TSOL18 plus 5 mg Quil A (Brenntag Biosector,
Frederikssund, Denmark). Vaccines were supplied in 10 dose vials
which were stored refrigerated over a period of up to 5 monthsch host farms were located and pigs were kept during the ﬁeld trial of the TSOL18
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vaccine may have been exposed to ambient temperature (up to
40 C) for periods up to 12 h. Rehydrated vaccines were used as
soon as possible although these may have been exposed to ambi-
ent temperature for up to 2 h before injection. Pigs received their
ﬁrst immunisation approximately 2 weeks after they had been
placed with their host farm. Pigs were 2–3 months of age at the
time of the ﬁrst immunisation with 1 ml vaccine injected intra-
muscularly near the base of the ear. A second, identical immunisa-
tion was given after an interval of approximately 4 weeks. At the
time of the second injection all pigs, both vaccinated and controls,
received oxfendazole (Dolthene Merial) per os at a dose rate of
30 mg/kg which typically was approximately 15 ml per animal.
Approximately 3 months after the second immunisation, vacci-
nated pigs received a third injection of vaccine i.e. when the ani-
mals were about 6 months of age. Blood samples were obtained
from all animals via the jugular vein at the time of each treatment
as well as 2 and 9 weeks after the second immunisation, 2 weeks
after the third immunisation and at necropsy. Serum was sepa-
rated and stored at 20 C. Any animals that became unavailable
during the trial were investigated to determine the circumstances
that led to this happening. Farmers were paid 8000 FCFA (12 Euro)
every month for hosting the animals during the trial.
Pigs were slaughtered between 12–13 months of age. The brain
and musculature from half of the carcase, split longitudinally, were
dissected from the carcase and the number and viability of cysti-
cerci determined as described by Flisser et al. (2004). Where it
was clear that there were many hundreds of cysticerci in a carcase,
the total number in muscle was estimated by selecting two, 1 kg
muscle samples from different regions of the carcase, counting
carefully the number of viable and non-viable cysts in those sam-
ples to obtain a mean number per kg and estimating the total num-
ber in the remaining half of the carcase from the weight of the
associated half carcase musculature. On every occasion the num-
bers in the entire heart and brain were determined precisely.
Serum antibody titres to TSOL18 vaccine in vaccinated pigs
were obtained by ELISA using TSOL18 expressed as a maltose bind-
ing protein (MBP) fusion as described by Kyngdon et al. (2006).
Plates (Nunc, Polysorb) were incubated with 100 lg per well of
TSOL18-MBP (5 lg/ml) in carbonate-bicarbonate buffer, pH 9.6
for 1 h at 37 C and overnight at 4 C. Antigen was discarded and
wells incubated with 150 ll of PBS plus 2% new-born calf serum,
0.05% Tween20 (PBS-NBCS-T) for 1 h at 37 C. After washing the
plates, test sera were serially diluted from 1/100 to 1/102,400 in
PBS-NBCS-T and plates incubated for 1 h at 37 C. Bound speciﬁc
antibody was detected after washing the plates and addition of
100 ll of rabbit anti-pig IgG peroxidase conjugate (SIGMA) at opti-
mal dilution followed by adding the chromogen/substrate solution
consisting of orthophenylene diamine (DAKO, #S2045) and H2O2 as
per the manufacturer’s directions. Plates were incubated at 30 C
for 15 min, the reaction was stopped with 50 ll/well of 4 N
H2SO4 and the absorbance measured at 492 nm (Multiscan EX,
Termo Labsystems). Titres were calculated as the dilution of serum
at which the O.D. equalled 0.5. Geometric mean titres were calcu-
lated; a titre of 50 was used in those cases where the O.D. at 1:100
of a vaccinated animal’s serum was greater than the mean + 2 S.D.
of the value for control sera at 1:100, but less than O.D. 0.5.
McNemar’s test was used to compare the proportion of paired
vaccinated pigs that were infected with the proportion of control
pigs that were infected. Comparison of the number of cysts in vac-
cinated and control paired pigs was evaluated by Wilcoxon’s
signed rank test. Spearman’s rank correlation coefﬁcient was used
to assess the association between the number of cysts in the mus-
cles and the number of cysts in the brain in the 102 control pigs,
and in the 20 control pigs which had cysts in the muscles. Stata/
SE 11.0 for Windows (StataCorp, College Station, TX, USA) softwarewas used and a two-sided P-value < 0.05 was considered to be sta-
tistically signiﬁcant.
Over the duration of the trial, a total of 28 pigs became unavail-
able for follow-up, 10 from the vaccinated group and 18 control
animals. The majority had been killed and consumed by a neigh-
bour. No necropsy information was obtained from these animals.
TSOL18 vaccinations were well tolerated by the animals with no
adverse reactions noted or reported by the keepers of the pigs. At
necropsy no lesions were identiﬁed that were likely to have been
associated with the injections.
Twenty control animals (of 102 available at the end of the trial)
were found to harbour cysticerci when autopsies were undertaken
when the pigs were 12–13 months of age, representing a preva-
lence of 19.6%. Numbers of cysticerci ranged from three cysts to
more than 37,000 cysts. Thirteen animals had an estimated para-
site burden of P1000 cysticerci. All infected animals were found
to have viable cysticerci and 98% of the total number of cysts found
were viable. The mean number of viable cysts in infected animals
was 7142. Three animals were found to have non-viable cysticerci
also. Fifteen animals had cysticerci in the brain as well as the mus-
cle. All animals with cysts in the brain had viable cysts with 97% of
the brain cysts being viable. Three animals had non-viable as well
as viable cysts in the brain.
At the completion of the trial, 97 of the control/vaccinated
paired pigs had both animals available for necropsy. Eighteen ani-
mals which were available for necropsy, comprising ﬁve control
animals and 13 vaccinated animals, had their partner unavailable
for necropsy. Data concerning all animals which were necropsied
(97 pairs plus 18 unpaired animals) are detailed in Table 1. No cys-
ticerci were found at necropsy anywhere in any of the vaccinated
animals, including both those for which the paired control animals
was necropsied as well as the 13 vaccinated animals for which the
pair partner was not available for necropsy. Statistical comparison
of the pairs of control and vaccinated animals (Table 1) showed a
signiﬁcant reduction in vaccinated animals in total cysts
(P < 0.0001), viable cysts in muscles (P < 0.0001), total cysts in
the brain (P = 0.0002) and viable cysts in the brain (P = 0.0002).
There was a reduction in the prevalence of infection from 19.6%
(19/97) in paired control pigs to 0% (0/97) in paired vaccinated pigs
(P < 0.0001) (Table 2). Spearman’s correlation coefﬁcient was 0.89
(95% Conﬁdence Interval (CI) 0.84 to 0.92, P < 0.0001, n = 102)
when assessing the association between total number of cysts in
the muscles and total number of cysts in the brain. The correlation
was 0.92 (95% CI 0.81 to 0.97, P < 0.0001) for the 20 pigs with cysts
in the muscles. Cysts in the brain only occurred in pigs with at least
479 cysts in the muscles (Table 1).
Speciﬁc antibody titres against TSOL18 in vaccinated pigs are
shown in Fig. 2. All vaccinated animals developed detectable titres
of antibody following the initial immunisation. The titre was
boosted to a geometric mean titre of 750 detected 2 weeks after
the second immunisation. A single animal failed to respond to
the second immunisation and a further 11 animals displayed rela-
tively poor responses having titres 6300. The response following
the third immunisation given 4 months after the ﬁrst injection
was pronounced, with speciﬁc antibody titres boosted to a geomet-
ric mean titre of 12,000. All those animals which responded poorly
to the second immunisation responded well to the third injection.
The animal which failed to respond to the second immunisation
had an anti-TSOL18 titre of 26,000 after the third immunisation.
With the exception of a single animal, all pigs had titres after the
third immunisation that were grater than the titre seen after the
second immunisation. At the time the animals were necropsied,
all vaccinated animals remained seropositive, with titres ranging
from 160 to 4000.
Vaccination with TSOL18 prevented any detectable infection
with T. solium in pigs raised in circumstances where there was a
Table 1
Numbers of Taenia solium cysticerci in pairs of vaccinated and control pigs involved in a ﬁeld trial of the TSOL18 vaccine in the Mayo-Danay district of Cameroon. Animals were
distributed to different households as pairs comprising one control and one vaccinated animal. Cysticerci numbers were subsequently determined by detailed examination of
carcase musculature and the brain at necropsy. The number of cysticerci was determined in half the carcase musculature plus the entire heart. Numbers for the entire brain are
shown separately. Those animals for which both members of a pair were available for necropsy are shown as paired pigs while those where only one member of a pair was
available for necropsy are shown as unpaired pigs.
Total cysts in
control pig
Total cysts in
vaccinated pig
Frequency Muscle total
cysts
Muscle viable
cysts
Muscle non-viable
cysts
Brain total
cysts
Brain viable
cysts
Brain non-viable
cysts
Paired pigs
0 0 78 0 0 0 0 0 0
3 0 1 3 3 0 0 0 0
6 0 1 6 6 0 0 0 0
10 0 1 10 10 0 0 0 0
14 0 1 14 14 0 0 0 0
100 0 1 100 100 0 0 0 0
484 0 1 479 479 0 5 5 0
784 0 1 781 781 0 3 3 0
1000 0 1 987 987 0 13 13 0
1500 0 1 1491 760 731 9 7 2
1536 0 1 1527 820 707 9 6 3
2052 0 1 2041 2041 0 11 11 0
2120 0 1 2116 2116 0 4 4 0
4000 0 1 3985 3985 0 15 15 0
10,560 0 1 10,543 10,543 0 17 17 0
14,976 0 1 14,955 14,955 0 21 21 0
15,000 0 1 14,981 14,981 0 19 19 0
18,368 0 1 18,343 18,343 0 25 25 0
32,000 0 1 31,978 31,978 0 22 22 0
37,100 0 1 37,080 37,080 0 20 20 0
Unpaired pigs
0  4 0 0 0 0 0 0
3820  1 3812 2672 1140 8 7 1
 0 13 0 0 0 0 0 0
i-T
SO
L1
8 
tit
re
1000
10000
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protection is consistent with the ﬁndings of several previous vac-
cine trials which were carried out under controlled conditions
against an experimental challenge infection (Flisser et al., 2004;
Gonzalez et al., 2005; Lightowlers, 2006; Cai et al., 2008). When ap-
plied as two immunisations approximately 1 month apart, the vac-
cine induces complete or almost complete protection against a
challenge infection given within a few weeks of the second immu-
nisation. The duration of protection has not been deﬁned in exper-
imental challenge trials, however, data from the ﬁeld trial detailed
here indicates that two immunisations in young pigs, together
with a booster immunisation given when the animals are 6–
7 months of age, was sufﬁcient to protect the animals through until
the age at which they are generally slaughtered for consumption
(12–14 months). While it is unclear whether the third immunisa-
tion was required in order to maintain immunity to the end of
the trial, the antibody response of the pigs to TSOL18 was boosted
to a substantially greater level following the third immunisation
than seen after the second injection, suggesting that this may have
enhanced and prolonged the level of protection. Further ﬁeld trials
involving different groups given one, two or three immunisationsTable 2
Summary of the prevalence of infection with Taenia solium in pairs of vaccinated and
control pigs in a ﬁeld trial of the TSOL18 vaccine in relation to the presence or absence
of infection in the partner animal. Those animals for which data were available only
from one member of a pair are shown as individual animals, with the associated pair
indicated as unknown.
Taenia solium infection
status: vaccinates
+ve ve Unknown
Taenia solium infection status: controls +ve 0 19 1
ve 0 78 4
Unknown 0 13 5would be required in order to determine the minimum as well as
the optimal vaccine schedule in order to achieve a useful level of
protection from infection.
All pigs in the trial were given a single treatment with oxfen-
dazole at the time the vaccinated animals received their second
immunisation. The purpose of this treatment in the vaccinated
group of pigs was to eliminate any parasites that may already be
present in the muscles prior to the animals being rendered im-
mune to subsequent parasite challenge following vaccination.
The TSOL18 vaccine utilises an antigen which is present only in
the oncosphere and immediate post-oncospheral stages in the par-Lo
g 
an
t
100
PB 2wpV1 2wpV2 2wpV3 Nec
Fig. 2. Anti-TSOL18 antibody titres (geometric mean ± S.D.) in vaccinated pigs
following immunisation with TSOL18. Pigs received three immunisations and
serum samples obtained prior to the ﬁrst immunisation (PB) and 2 weeks after each
immunisation (2wpV1, 2wpV2, 2wpV3) as well as at the time of necropsy (Nec).
Antibody titres were determined against recombinant TSOL18 expressed as a
maltose binding protein fusion with sera serially diluted from 1:100 and the titre
calculated as the dilution at which the O.D. in ELISA equalled 0.5.
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has not speciﬁcally been tested for its effects on post-oncospheral
parasites, it is not anticipated to have any effect on established cys-
ticerci. Control animals were also given oxfendazole treatment so
as to allow any differences between the vaccinated and control
groups to be assigned speciﬁcally and uniquely to the TSOL18 vac-
cine. It is likely that a proportion of the piglets had already been
infected with cysticerci prior to their treatment with oxfendazole
and that the overall prevalence of T. solium infection of pigs in this
region exceeds the 19.6% detected in the control animals which
had received oxfendazole at 3–4 months of age. Many unvacci-
nated animals harboured heavy burdens of infection suggesting
that they had directly eaten faeces of a tapeworm carrier. In the
Mayo-Danay region of far North Cameroon 90% of pigs are free
roaming and more than 40% of houses that keep pigs do not have
latrines (Assana et al., 2010). The limited available data suggests
that T. solium infection is hyperendemic in northern Cameroon
(Assana et al., 2001; Zoli et al., 2003).
In Cameroon as well as many other regions of the world, neuro-
cysticercosis is a signiﬁcant cause of human morbidity and mortal-
ity. There is increasing interest in developing new disease control
tools for T. solium and in deﬁning control measures that could lead
to elimination of the disease (Garcia et al., 2007). The vaccine ﬁeld
trial described here has found that a relatively simple procedure
combining the TSOL18 vaccine with a single oxfendazole treatment
has the capacity to be implemented as an effective measure to con-
trol transmission of T. solium through pigs. Implementation of this
approach could potentially lead to a reduction in the number of
human taeniasis cases and, thereby, reduction in the number of
new human cases of neurocysticercosis. An advantage of using a
combination vaccination plus chemotherapy approach to cysticer-
cosis control in pigs, in comparison to using chemotherapy alone, is
that use of the vaccine allows a sufﬁcient period of time to elapse
after chemotherapy for any lesions in the meat caused by necrotic
cysticerci to be resolved prior to the animals being slaughtered for
consumption. During this period, all animals (previously infected
or otherwise) are protected against T. solium infection by the
vaccine.
In this ﬁeld trial the potential for transmission of T. solium was
eliminated in the treated animals. TSOL18 vaccination plus chemo-
therapy in pigs may be a relatively sustainable procedure applica-
ble on a wide scale. It could be anticipated that a combination of
both vaccination/oxfendazole treatment of pigs together with
anthelmintic treatment of the human population to eliminate the
adult tapeworms, particularly when control procedures were ﬁrst
implemented, would have the greatest and most rapid impact on
reducing the incidence of neurocysticercosis (Lightowlers, 1999).
The data presented here represent a proof-of-principal, demon-
strating the potential of pig vaccination to control T. solium trans-
mission; it may not present a protocol that would be readily
acceptable for ﬁeld use. At present, the TSOL18 vaccine is applied
as a minimum of two intramuscular immunisations. Future
improvements in the vaccine, in relation to minimizing the num-
ber of exposures to the recombinant antigen required to induce/
maintain protection, and changing the method of delivery from
parenteral to an oral route, would enhance the ease with which
the vaccine could be applied in undertaking T. solium control.
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